Pharmafile Logo
Pharmafocus logo
Advanced Search
biogen_austria_238

NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay

August 14, 2018
Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …

News
staphylococcus_aureus_50000x_usda_ars_emu

Researchers design new class of drugs to counter cardiovascular disease

August 14, 2018
Manufacturing and Production TMAO, cardiovascular, gut microbe, heart attack, research

Cleveland Clinic researchers have designed a potential new class of drugs that may reduce the risk of cardiovascular disease by …

News
cancer-vs-alzheimer-1080x810

“Radical radiotherapy” cuts required treatments from 37 to 5

August 14, 2018
Manufacturing and Production Cancer, oncology, pharma, radiotherapy

Researchers at Queen’s University Belfast have been trialling a new form of “radical radiotherapy” which can be delivered in just …

News
3922609891_dced293244_z

Rare lung cancer drug approved in Scotland

August 14, 2018
Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer

The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …

News
nawal_ouzren_-_sensorion_alt

Working Life: Nawal Ouzren, CEO of Sensorion

August 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Interview, Sensorion, Working Life, feature, pharma

Pharmafocus caught up with Sensorion CEO Nawal Ouzren to take a look at her path throughout her career and get …

Feature
chris-collins_getty_images

Indicted GOP congressman Chris Collins’ terminates re-election campaign

August 13, 2018
Medical Communications, Sales and Marketing Chris Collins, Innate Therapeutics, US, pharma

Indicted republican congressman Chris Collins has performed a U-turn since his arrest on Wednesday under allegations of insider trading, confirming …

News

Astellas acquires gene therapy group Quethera in £85 million deal

August 13, 2018
Sales and Marketing Astellas, Japan, gene therapy, ocular, quethera, vision

The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million. …

News
5204602349_c87b204860_z

FDA approves RNA therapy for rare genetic disease

August 13, 2018
Sales and Marketing FDA, Onpattro, Orphan Drugs, RNA, rare diseases

The US Food and Drug Administration has approved the RNA-based therapy Onpattro, for the treatment of the rare genetic disease …

News
abbvie_0

Chicago Judge overturns $140 million AbbVie AndroGel verdict

August 13, 2018
Sales and Marketing AbbVie, Litigation, androgel, legal, testosterone

A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc. The verdict, which ruled in …

News
fdaoutsideweb

FDA approves first oral therapy for rare Fabry disease

August 13, 2018
Sales and Marketing FDA, Fabry disease, US, pharma

Amicus has revealed that its therapy Galafold (migalastat) has been awarded approval by the FDA in the treatment of adult …

News
nhs_sign

NHS scraps restriction on availability of J&J’s Imbruvica in leukaemia patients

August 10, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, NHS, NICE, UK, imbruvica, leukaemia, pharma

The NHS has dropped a controversial restriction preventing leukaemia patients from accessing Johnson & Johnson’s tyrosine kinase inhibitor Imbruvica (ibrutinib), …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

August 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ADHD, Allergan, MHRA, UK, brexit, iraq, pharma, top 10

There was some clarity on Brexit this week as the MHRA set out a plan for the implantation period set …

News

Letters to doctors reduce opioid prescriptions, study shows

August 10, 2018
Medical Communications OxyContin, USA, fentanyl, opioid, opioid crisis, research, study

A study has shown that Doctors who received a letter from the medical examiner’s office informing them of their patient’s …

News
fda2outsideweb

FDA approved more generics in July than any previous month

August 10, 2018
Medical Communications FDA, generics, pharma

FDA Commissioner Scott Gottlieb took to Twitter to announce the news that the FDA smashed its previous record for number …

News
4768764591_9e4f7f0eb8_z

ABPI Chief warns of Brexit impact on EU

August 10, 2018
Medical Communications ABPI, EU, UK, brexit, trade lobby

The head of the Association of the British Pharmaceutical Industry (ABPI) has warned that European governments have failed to recognise …

News
rep

US Congressman arrested over insider trading in biopharma firm

August 9, 2018
Research and Development, Sales and Marketing Chris Collins, Innate, Innate Immunotherapeutics, US, congress, multiple sclerosis, pharma

A Republican Congressman has been arrested by the FBI over on charges of insider trading with shares in Australian biopharmaceutical …

News
16792957331_d9572dbdf4_z

FDA expands list of valsartan recalls

August 9, 2018
Medical Communications China, FDA, US, heart medication, recall, valsartan

The US Food and Drug Administration (FDA) has expanded a list of products containing valsartan that are to be recalled. …

News

NICE recommends Eli Lilly’s psoriatic arthritis drug

August 9, 2018
Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …

News

NICE recommends Pfizer’s Besponsa in rare leukaemia following review

August 9, 2018
Sales and Marketing NICE, Pfizer, leukaemia, pharma

Pfizer has revealed that NICE has finally decided to recommend its CD22-targeting monoclonal antibody Besponsa (inotuzumab ozogamicin) in the treatment …

News

Insys Therapeutics reaches $150m agreement to settle opioid marketing case

August 9, 2018
Medical Communications, Sales and Marketing Litigation, Subsys, US Department of Justice, fentanyl, insys, opioid, pharma

The Arizona-based pharma company Insys Therapeutics has reached an agreement to pay $150 million to the US Department of Justice …

News
The Gateway to Local Adoption Series

Latest content

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026

Everdrone appoints David Borkmann as Senior Medical Advisor

January 28, 2026

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026